Price movement over the last 24 hours
Align Technology, Inc. vs JPMorgan Ultra Short Income ETF — how do they compare? Align Technology, Inc. trades at $179.45 (market cap $12.86B), while JPMorgan Ultra Short Income ETF trades at $50.43. The key difference: Align Technology, Inc. is trading nearer its 52-week high, JPMorgan Ultra Short Income ETF nearer its low. Which is the better fit depends on your goals.
| ALGN | JPST | |
|---|---|---|
Market Cap | $12.86B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $207.19 | $50.78 |
52-Week Low | $124.88 | $50.40 |
Enterprise Value | $11.92B | — |
Signals from Pluang's Aura AI — not financial advice
Align Technology (ALGN) trades at $179.45, up 0.72% with a bullish technical outlook from moving averages. The company maintains solid profitability with a 10.5% net margin and has beaten EPS estimates for three consecutive quarters. Recent developments include a new manufacturing facility in India and upcoming Q2 2026 earnings on July 29, 2026.
ALGN offers growth potential with a consensus price target of $218.40, representing 22% upside, supported by 73% analyst buy ratings. Risks include European regulatory scrutiny and North American demand pressures. The stock's valuation at 30x P/E requires sustained earnings growth to justify further gains.
JPST, the JPMorgan Ultra-Short Income ETF, trades at $50.45 with no recent price change. The technical outlook is bearish based on moving averages, while oscillators are neutral. The fund focuses on high-quality, short-term bonds, offering a cash alternative with low duration risk. Recent news highlights its role in rising rate environments and strong flows into active ETFs.
The outlook for JPST is stable, appealing to risk-averse investors seeking income and capital preservation amid interest rate uncertainty. Key risks include interest rate sensitivity and credit spread changes. Institutional interest is growing, but the bearish technical signal warrants caution for short-term traders.
Trailing returns across standard periods
Align is the leading manufacturer of clear dental aligners globally, having pioneered the technology with the introduction of its Invisalign branded aligners in 1998. Since then, Invisalign has become a household name, having treated over 10 million patients with malocclusion (misaligned teeth) through orthodontist and dentist-guided treatment plans. The company maintains dominant market share of clear aligners, despite the introduction of direct-to-consumer competitors upon the expiration of key patents that began in 2017. Align also manufactures intraoral scanners (iTero), used for orthodontic treatment and restorative dental procedures (digital models for crowns, veneers, and implants).
Read more on ALGN →JPST is an actively managed ETF that invests in short-term, investment-grade fixed income securities. It aims to provide current income and capital preservation while maintaining high liquidity.
Read more on JPST →